Immunocore Takes Key Steps with Brenetafusp
Immunocore, a biotechnology firm dedicated to creating innovative immunomodulating treatments, has revealed important findings from the Phase 1 trials of brenetafusp, an ImmTAC bispecific that targets PRAME in ovarian cancer patients who are resistant to platinum therapy. These results were shared at a notable medical conference, showcasing that brenetafusp is effective as a standalone treatment and can also be safely integrated with chemotherapy.
Activity and Safety Insights from the Trials
The study involved patients who had undergone numerous treatments, showing that brenetafusp alone achieved an impressive disease control rate. Among those with heavily pre-treated, platinum-resistant ovarian cancer, the treatment showed significant clinical activity, evidenced by disease control and molecular responses.
David Berman, the Head of Research and Development at Immunocore, emphasized the promising early effectiveness indicated by the data. He noted that brenetafusp exhibited substantial characteristics of clinical activity, warranting further investigation in earlier treatment stages for ovarian cancer.
Study Design and Outcomes
The clinical trial consisted of 37 participants, each with a median of five prior treatment lines. Notably, 81% of these individuals had previously received bevacizumab, while 59% had undergone treatment with PARP inhibitors. Importantly, there were no treatment-related discontinuations, which speaks to the therapy’s acceptability among patients.
Among those assessable, about 58% showed disease control, including partial responses and stable disease outcomes. This level of efficacy suggests that brenetafusp may be an important new option in the ovarian cancer treatment landscape.
Outcomes from Combination Therapies
In another part of the trial, 16 patients with platinum-resistant ovarian cancer were treated with a combination of brenetafusp and different chemotherapy agents, like gemcitabine and nab-paclitaxel. The results were equally encouraging, showcasing a 69% disease control rate among assessable patients. Historical data shows that patients in such heavily treated scenarios often had less than a 10% response rate from standard chemotherapy, highlighting brenetafusp's combination therapy as a significant advantage.
T Cell Fitness and Its Impact on Efficacy
Key findings from the trial underscored the significance of T cell fitness gene expression signatures in forecasting clinical outcomes. Patients with higher T cell fitness signatures demonstrated better disease control and progression-free survival than those with lower expressions. This points toward potential strategies for patient stratification and tailored treatment plans.
Wider Implications for Immunocore's Developments
Immunocore is committed to advancing its ImmTAC technology, which has shown potential in treating various cancers by effectively mobilizing the immune system against tumor cells. The technology is being adapted for use in other cancers and varied treatments, reflecting the company’s extensive pipeline in oncology.
As research around brenetafusp progresses, insights gained from multiple studies will likely play a crucial role in shaping the future development and optimization of therapies designed to leverage the immune system's capabilities.
Frequently Asked Questions
What is brenetafusp?
Brenetafusp is an ImmTAC bispecific therapy created by Immunocore that targets the PRAME antigen to activate T cells against cancer.
How does brenetafusp function?
Brenetafusp functions by redirecting the immune system, particularly T cells, to recognize and eliminate cancer cells expressing the PRAME antigen.
What are the key outcomes from the Phase 1 trial?
The Phase 1 trial revealed promising efficacy and safety for brenetafusp, showing significant disease control in patients who had undergone extensive prior treatments.
Is brenetafusp compatible with chemotherapy?
Yes, findings indicate that brenetafusp can be safely used alongside chemotherapy, improving clinical outcomes in comparison to chemotherapy alone.
What are Immunocore's plans going forward?
Immunocore intends to continue researching brenetafusp, including exploring trials in early treatment stages and other combination therapies.
